Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas

Journal of Pathology

Volumn 215, Issue 3, 2008, Pages 290-299

  Chen, D R ^a   Chu, C Y ^b   Chen, C Y ^c   Yang, H C ^d   Chiang, Y Y ^e   Lin, T Y ^c   Chiang, I P ^c   Chuang, D Y ^d   Yu, C C ^b   Chow, K C ^d  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b FENG YUAN HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^e CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Hepatocyte growth factor; Interleukin 6; Lung adenocarcinoma; Oncostatin M; Oncostatin M receptor

Indexed keywords

INTERLEUKIN 6; ONCOSTATIN M; ONCOSTATIN M RECEPTOR; SCATTER FACTOR; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3;

ARTICLE; CANCER SURVIVAL; CELL GROWTH; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; CELL MEMBRANE; CHI-SQUARE DISTRIBUTION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MICROSCOPY, CONFOCAL; ONCOSTATIN M; ONCOSTATIN M RECEPTOR BETA SUBUNIT; PROGNOSIS; RECEPTORS, ONCOSTATIN M; RECEPTORS, OSM-LIF; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; SURVIVAL RATE;

EID: 46849090572     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2361     Document Type: Article

References (23)

1. Rosell R, Moran T, Fernanda Salazar M, Mendez P, De Aguirre I, Ramirez JL, et al. The place of targeted therapies in the management of non-small cell bronchial carcinoma. Molecular markers as predictors of tumor response and survival in lung cancer. Rev Mal Respir 2006;23:16S131-16S136.
2. Schaefer G, Shao L, Totpal K, Akita RW. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. Cancer Res 2007;67:1228-1238.
3. Chen JT, Lin TS, Chow KC, Huang HH, Chiou SH, Chiang SF, et al. Cigarette smoking induces overexpression of HGF in type II pneumocytes and lung cancer cells. Am J Respir Cell Mol Biol 2006;34:264-273.
4. Yanagita K, Matsumoto K, Sekiguchi K, Ishibashi H, Niho Y, Nakamura T. Hepatocyte growth factor may act as a pulmotrophic factor on lung regeneration after acute lung injury. J Biol Chem 1993;268:21212-21217.
5. Cohen M, Marchand-Adam S, Lecon-Malas V, Marchal-Somme J, Boutten A, Durand G, et al. HGF synthesis in human lung fibroblasts is regulated by oncostatin M. Am J Physiol Lung Cell Mol Physiol 2006;290:L1097- 1103.
6. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374:1-20.
7. Diveu C, Venereau E, Froger J, Ravon E, Grimaud L, Rousseau F, et al. Molecular and functional characterization of a soluble form of oncostatin M/interleukin-31 shared receptor. J Biol Chem 2006;281:36673-36682.
8. Mosley B, De Imus C, Friend D, Boiani N, Thoma B, Park LS, et al. Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem 1996;271:32635-32643.
9. Hermanns HM, Radtke S, Haan C, Schmitz-Van de Leur H, Tavernier J, Heinrich PC, et al. Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130. J Immunol 1999;163:6651-6658.
10. Ozoren N, El-Deiry WS. Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol 2003;13:135-147.
11. Wang LS, Chow KC, Wu CW. Expression and up-regulation of interleukin-6 in oesophageal carcinoma cells by n-sodium butyrate. Br J Cancer 1999;80:1617-1622.
12. Chow KC, Chiou SH, Ho SP, Tsai MH, Chen CL, Wang LS, et al. The elevated serum interleukin-6 correlates with the increased serum butyrate level in patients with nasopharyngeal carcinoma. Oncol Rep 2003;10:813- 819.
13. Hsieh CC, Chow KC, Fahn HJ, Tsai CM, Li WY, Huang MH, et al. Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. Ann Thorac Surg 1998;66:1159-1163.
14. Geldner N, Jurgens G. Endocytosis in signalling and development. Curr Opin Plant Biol 2006;9:589-594.
15. Dasari V, Gallup M, Lemjabbar H, Maltseva I, McNamara N. Induction of Epithelial-mesenchymal transition in lung cancer: is tobacco the 'smoking gun'? Am J Respir Cell Mol Biol 2006;35:3-9.
16. Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors. Cell Res 2004;14:359-372.
17. Schneider P, Bodmer JL, Holler N, Mattmann C, Scuderi P, Terskikh A, et al. Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. J Biol Chem 1997;272:18 827-18 833.
18. Boniface K, Diveu C, Morel F, Pedretti N, Froger J, Ravon E, et al. Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation. J Immunol 2007;178:4615-4622.
19. Daniels RA, Turley H, Kimberley FC, Liu XS, Mongkolsapaya J, Ch'En P, et al. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res 2005;15:430-438.
20. Lacreusette A, Nguyen JM, Pandolfino MC, Khammari A, Dreno B, Jacques Y, et al. Loss of oncostatin M receptor beta in metastatic melanoma cells. Oncogene 2007;26:881-892.
21. Ng G, Winder D, Muralidhar B, Gooding E, Roberts I, Pett M, et al. Gain and overexpression of the oncostatin M receptor occur frequently in cervical squamous cell carcinoma and are associated with adverse clinical outcome. J Pathol 2007;212:325-334.
22. Cagini L, Monacelli M, Giustozzi G, Moggi L, Bellezza G, Sidoni A, et al. Biological prognostic factors for early stage completely resected non-small cell lung cancer. J Surg Oncol 2000;74:53-60.
23. Matsumoto K, Nakamura T. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 2003;94:321-327.